Pharma IQ Members

Georger

George Clinical harnessing innovation to improve patient retention in clinical trials

George Clinical’s parent organisation, The George Institute for Global Health and its TEXTCARE application, has been named a top 10 finalist in this year’s Google Impact Challenge. With a top prize of AUD $750,000, The George Institute has the opportunity to use its proven text messaging platform to tackle chronic disease on a global scale.

by: George Clinical Representative
Published: October 21, 2016
Tags:


Georger

EDC Platform Investment Is Critical To A CRO’s Survival

As the costs and complexities of running clinical trials increase, so does the impetus, indeed obligation, to invest in fully integrated eSystems that are essential to simplifying the overall clinical trial process.

by: George Clinical Representative
Published: October 11, 2016
Tags:


Georger

Case Study: Scientific Leadership in complex, multi-regional trials boosts recruitment across the board

The scientific leadership model for conducting clinical trials is relatively new. Despite its novelty, scientific leadership continues to prove its worth when comparing recruitment metrics both before and after the addition of scientific leadership into some of the world’s most complex, multi-regional trials. The implementation of scientific leadership into any clinical trial has shown to motivate and engage investigators, many of whom maintain their connection with the scientific leader (and their affiliate CRO), long after any one trial finishes. As such, the scientific leadership model illustrates its utility through its capacity to develop (and maintain) robust, engaged clinical networks from which to draw data of the highest scientific standards.

by: George Clinical Representative
Published: October 4, 2016
Tags:


Georger

Investigator networks cultivated through risk-factor trials, drives data diversity in dementia research.

Extensive investigator networks, cultivated over the course of some of the world’s largest clinical trials into the risk factors for dementia, present an exciting opportunity for the future of dementia trials. Diabetes, hypertension, stroke, vascular disease, smoking, poor diet, physical inactivity and even depression have been linked to an increase in the likelihood of an individual presenting with dementia at some point in their lives

by: George Clinical Representative
Published: August 2, 2016
Tags: investigator network, clinical, clinical trials, clinical trial supply. george clinical, dementia, dementia trials, George Institute for Global Health, Dr Candice Delcourt, Professor Bruce Neal, Professor Craig Anderson


Georger

Utilizing Clinical Research Organizations for late Phase I studies

A key step in developing a new drug is the transition from the laboratory to the human subject in a Phase I clinical trial, where the new compound is given to humans for the first time. A Phase I trial is the gateway between scientific research and clinical medicine. Generally, in-human Phase I studies are conducted in healthy male patients or healthy male volunteers; however later Phase I-Ib trials are conducted in-human with the affected disease the compound is intended to treat.

by: George Clinical Representative
Published: February 24, 2016
Tags:


Georger

Lowering blood pressure to decrease risk of cardiovascular events

Globally, there are millions of people that could benefit from an intensive lowering of blood pressure (BP). An individual with lower BP decreases their chances of suffering from any cardiovascular events such as: stroke, heart disease or heart attacks. A new study shows that lowering blood pressure to less than 140 mm Hg, the current treatment standard, had significant benefits.

by: George Clinical Representative
Published: February 1, 2016
Tags:


Georger

The Changing Role of the Data Manager

Throughout clinical trials, the data manager (DM) is heavily involved in constructing databases, managing reports, programming quality checks and managing the collection of data in the clinical trial. The DM is responsible for managing and training users the concepts of computerised clinical data base systems as well as fulfilling other duties such as design basic reports for investigators, entering data into protocol-specific forms and ensure there is high level of quality and integrity of data. The roles that the DM play is fast changing with the prevalence of electronic data capture (EDC) as the preferred platform for data collection

by: George Clinical Representative
Published: January 4, 2016
Tags: clinical trial supply